Preclinical Services for Biopharmaceutical Product Development
$3,408N01FY2023AINIH
Allucent Government Services (Us) Llc, Cary NC
Investigators
Abstract
The Biopharmaceutical Product Development Services program provides services to facilitate preclinical development of materials that are derived from biotechnology processes, such as monoclonal antibodies and derivatives of monoclonal antibodies; recombinant proteins; peptides; nucleic acid based vectors (siRNA, plasmids); and live, modified-live and/or attenuated entities. Services include: product development planning and evaluation; assay development and product characterization; process development and formulation; GMP manufacturing; and regulatory CMC documentation support. The aim is advance translational research for infectious diseases.
View original record on NIH RePORTER →